This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
Yesterday’s UK 100 Leaders | Price (p) | % Chg |
HARGREAVES LANSDOWN PLC | 1,411.0 | 4.6% |
INTL CONSOLIDATED AIRLINE-DI | 104.9 | 4.4% |
GVC HOLDINGS PLC | 1,011.0 | 4.1% |
RENTOKIL INITIAL PLC | 537.2 | 3.9% |
LLOYDS BANKING GROUP PLC | 27.9 | 2.8% |
Yesterday’s UK 100 Laggards | Price (p) | % Chg |
FRESNILLO PLC | 1228.5 | -3.7% |
OCADO GROUP PLC | 2342.0 | -3.4% |
BAE SYSTEMS PLC | 442.3 | -4.9% |
DS SMITH PLC | 294.8 | -2.1% |
HOMESERVE PLC | 1147.0 | -1.9% |
Major World Indices | Price | % Chg | 1 YEAR |
UK 100 INDEX | 5,786 | 0.2% | -20.3% |
DOW JONES INDUS. AVG | 28,364 | 0.5% | 5.7% |
DAX INDEX | 12,543 | -0.1% | -1.7% |
NIKKEI 225 | 23,548 | 0.3% | 4.1% |
S&P/ASX 200 INDEX | 6,167 | -0.1% | -7.6% |
Commodities | Units | Price | % Chg |
WTI Crude Oil (Nymex) | USD/bbl. | 39.81 | -0.55% |
Brent Crude (ICE) | USD/bbl. | 41.55 | -0.43% |
Gold Spot | USD/t oz. | 1,914 | -0.6% |
Copper (Comex) | USd/lb. | 318 | -0.6% |
UK 100 called to open +6 points this morning at 5791. The UK 100 is set to rise this morning after Boris Johnson confirmed a trade deal with Japan – Britain’s first since Brexit vote. The market received an additional boost to sentiment with the news that the US Food and Drug Administration (FDA) has approved Veklury, the coronavirus (COVID-19) treatment from Gilead Sciences that was formerly known as Remdesivir. Asian markets picked up the baton this morning, with Japan’s Nikkei 225 up 81 points at 23,555 and Hong Kong’s Hang Seng up 153 points at 24,939.
Barclays
None
US Presidential Debate
German Markit Manufacturing PMI
Eurozone Markit PMI
UK Markit PMI Composite
UK Retail Sales
UK 100:
Unilever
UK 250:
Foresight Solar Fund
City of London Investment Trust
Hilton Food Group
Vesuvius
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.